<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03657134</url>
  </required_header>
  <id_info>
    <org_study_id>17-01618</org_study_id>
    <nct_id>NCT03657134</nct_id>
  </id_info>
  <brief_title>Introductory Clinical Trial for Measuring Patients Before, During, and After an Electrophysiology (EP) Procedure With a Novel, Body-Worn Sensor</brief_title>
  <official_title>Introductory Clinical Trial for Measuring Patients Before, During, and After an Electrophysiology (EP) Procedure With a Novel, Body-Worn Sensor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Subjects will be consented to wear the CoVa TM 2 prior to, during, and after an
      Electrophysiology Procedure. During this time, the system will measure the following
      parameters from subjects: heart rate (HR), Heart Rate Variability (HRV), respiration rate
      (RR), and Cardiac Output (CO). Data will be retrospectively analyzed to determine if the
      system effectively operates under these conditions, and can effectively monitor subjects and
      allow them to be discharged early from the hospital. Subjects will not be measured while
      transferred in and out of the operating room. Approximate sample size is 20 subjects.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 15, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Discharge</measure>
    <time_frame>1 Week</time_frame>
    <description>Number of days patients spend in hospital post surgery</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Ventricular Tachycardia</condition>
  <arm_group>
    <arm_group_label>EP Procedure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient will continuously wear the CoVa TM 2 system until they are discharged for period of about 24 hours. During this period, data from the sensor will be sent to the Gateway and Cloud- based System, and then analyzed retrospectively.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>CoVa 2 Sensor</intervention_name>
    <description>Upon completion of EP procedure, CoVa 2 sensor will be applied until discharge. Data from the sensor will be sent to the Gateway and Cloudbased system and analyzed retrospectively.</description>
    <arm_group_label>EP Procedure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with arrhythmias and other cardiac conditions that are scheduled for EP
             procedures.

          2. Subject is over 22 years of age at the time of consenting

          3. Subject and/or legally authorized representative is willing to undergo the informed
             consent process prior to enrollment in the study

        Exclusion Criteria:

          1. Pregnant subjects

          2. Subjects who are participating in another clinical study that may affect the results
             of either study

          3. Subjects who are unwilling or unable to wear the sensor (and electrodes) for a period
             of up to 14 hours

          4. Subjects who are considered by the principle investigator to be medically unsuitable
             for study participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lior Jankelson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Langone Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>April Jacobs</last_name>
    <phone>212 263 7704</phone>
    <email>April.Jacob@nyulangone.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Larry Chinitz, MD</last_name>
    <phone>212 263 5555</phone>
    <email>Larry.Chinitz@nyulangone.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>New York University School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>April Jacob</last_name>
      <phone>212-263-7704</phone>
      <email>April.Jacob@nyulangone.org</email>
    </contact>
    <investigator>
      <last_name>Larry Chinitz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lior Jankelson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>August 8, 2018</study_first_submitted>
  <study_first_submitted_qc>August 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 4, 2018</study_first_posted>
  <last_update_submitted>January 3, 2020</last_update_submitted>
  <last_update_submitted_qc>January 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

